bomedemstat
Phase 2- Indications
- Essential thrombocythemia, Myelofibrosis, Polycythemia vera
Company intelligence / Profile preview
Imago BioSciences, Inc.
San Francisco, California, United Statesmerck.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Imago BioSciences was evaluating Bomedemstat, an orally available small molecule inhibitor of LSD1, in two Phase 2 clinical trials for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF) before being acquired by Merck.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Imago BioSciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Imago BioSciences, Inc..